Home › Seizures › Ohio › Cleveland
Seizures clinical trials in Cleveland, OH
5 studies for Seizures are looking for participants at sites in and around Cleveland (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures
RecruitingPhase 2
- Neurology Institute Epilepsy Center of Cleveland Clinic, Cleveland
Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1
RecruitingPhase 3
- Cleveland Clinic, Cleveland
A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome
RecruitingPhase 3
- Cleveland Clinic, Cleveland
A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)
RecruitingPhase 3
- Cleveland Clinic, Cleveland
A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures
RecruitingPhase 2
- Cleveland Clinic Foundation, Cleveland
About Seizures
Seizures are caused by sudden, abnormal electrical activity in the brain. They can be mild or severe. Learn about the types, causes, and treatments.
More about Seizures on MedlinePlus
Seizures trials in other cities
- Washington, DC13 studies
- New York City, NY12 studies
- Philadelphia, PA11 studies
- Houston, TX8 studies
- Boston, MA8 studies
- Birmingham, AL7 studies
- Miami, FL6 studies
- Dallas, TX6 studies
- Chicago, IL6 studies
- Durham, NC6 studies
- Cincinnati, OH6 studies
- Los Angeles, CA5 studies
Other studies in Cleveland
- Non-Small Cell Lung Cancer43 studies
- Cancer (all types)36 studies
- Breast Cancer35 studies
- Prostate Cancer34 studies
- Heart Failure33 studies
- Metastatic Cancer30 studies
- Ovarian Cancer30 studies
- Lung Cancer26 studies
- Colorectal Cancer24 studies
- Cardiovascular Disease22 studies
- Endometrial Cancer20 studies
- Acute Myeloid Leukemia20 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.